supp.ai
Discover Supplement-Drug Interactions
Disclaimer: The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The tool is not a substitute for the care provided… (more)
Last Updated: 3 years ago
drug:
Dexamethasone
supplement:
Arachidonate
Research Papers that Mention the Interaction
“These data suggest that a unique inflammatory mediator network regulates CRIg expression and point to a mechanism by which arachidonate and dexamethasone have reciprocal effects on inflammation.”
Regulation of CRIg expression and phagocytosis in human macrophages by arachidonate, dexamethasone, and cytokines.“ Dexamethasone treatment (1-100 nM for 20 h), which was earlier shown to dose-dependently down-regulate the 85 kDa phospholipase A2 and its activation by phorbol ester and zymosan, was here shown also to counteract the protein kinase C-independent activation and arachidonate release elicited by bacteria.”
Multiple C-terminal serine phosphorylation accompanies both protein kinase C-dependent and -independent activation of cytosolic 85 kDa phospholipase A2 in macrophages.“This occurs because DEX inhibits the IL-1-induced enhanced arachidonate release.”
“Our results suggest a possible link between arachidonate metabolites inhibited by indomethacin or dexamethasone and the genesis of cytochrome P-450 disfunction.”
“ Arachidonate and other long-chain fatty acids appear to inhibit the … ([3H]R2858), progestin ([3H]R5020), androgen ([3H]R1881) and glucocorticoid ( [3H]dexamethasone ) to the respective receptors in brain (neonatal cerebral cortex and hypothalamus-preoptic area, … prostate, with the exception of the potentiating effect on the brain estrogen receptors.”
“In contrast, arachidonate release was inhibited in dexamethasone treated macrophages.”
“Inhibition of phospholipase A2 with para-bromophenacyl bromide, dexamethasone or quinacrine, alone or in combination, blocked arachidonate release by 50%-60% but had no effect on EDRF production as assessed by cyclic GMP accumulation in mixed- or co-cultures of endothelial and vascular smooth muscle cells.”
“Protection was obtained by FPL 55712, a selective antagonist of sulfidopeptide leukotrienes, by diethylcarbamazine, an inhibitor of leukotriene biosynthesis, by BW 755C, a dual lipoxygenase and cyclooxygenase inhibitor, and by dexamethasone , which inhibits arachidonate release.”
“ Dexamethasone , given for shorter periods prior to arachidonate injection resulted in survival rates from 17% to 40%.”
“ Dexamethasone and the other inducers stimulated the release of arachidonate from phospholipids.”
Help us improve supp.ai, we'd love to hear your feedback: Submit Feedback